Mode
Text Size
Log in / Sign up
N/A N=26 Treatment

Does Endurance Improve With the Use of Passy-Muir Valve for Patients With Tracheostomy?

PMV · Exercise Endurance · Tracheostomy

Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: Six Minute Walk Test - First Paired Sessions — 413; 387 Feet — p=0.2795

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Open Tracheostomy (Other); PMV in place (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Gaylord Hospital, Inc
Primary completion
Jun 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Six Minute Walk Test - First Paired Sessions
413; 387 0.2795
PRIMARY
Six Minute Walk Test - Second Paired Sessions
350; 384.6
PRIMARY
Six Minute Walk Test - Third Paired Sessions
380; 357.5
PRIMARY
Average Change of Borg Rating of Perceived Exertion - First Paired Sessions
4.35; 3.65 0.3416
PRIMARY
Average Change of Borg Rating of Perceived Exertion - Second Paired Sessions
6; 5.8
PRIMARY
Average Change of Borg Rating of Perceived Exertion - Third Paired Sessions
4.5; 8
SECONDARY
Change in Heart Rate - First Paired Sessions
18; 15.4
SECONDARY
Change in Oxygen Saturation - First Paired Sessions
-3.6; -2.3
SECONDARY
Active Standing Time - First Paired Sessions
259; 257

Summary

The purpose of this study is to determine if the use of the Passy-Muir Valve improves endurance for patients in the Long Term Acute Care setting as measured with the Six- Minute Walk Test.

Eligibility Criteria

Inclusion Criteria

  • Individual with tracheostomy who can tolerate daily 30 minute Physical Therapy sessions with use of PMV and be able to maintain oxygen saturations above 88% with exertion.
  • Ability to understand and respond to simple verbal instructions and one step commands in English well enough to consent without any interpretation.
  • Ability to ambulate a minimum of 10 feet with/without assistive device and with/without physical assistance.

Exclusion Criteria

  • Active seizures
  • Active Pregnancy
  • Uncontrolled hypertension
  • Cognitive deficits that would disrupt ability to provide informed consent
  • Enteric infection control precautions
  • Ongoing orthostasis
  • Actively on decannulation protocol
  • Medical instability that would cause a doctor to put therapy program on hold
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04941456). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search